Table 3 Clinicopathological factors of 19 patients with Pan-NET who underwent evaluations of MGMT expression before STZ-based treatment.
Characteristics | Total n = 19 |
|---|---|
 Age, years, median (range) | 52 (27–75) |
 Sex, male/female | 9/10 |
Genetic syndrome | |
 MEN type 1 | 0 |
 VHL | 0 |
Tumor factor | |
 Tumor size, mean ± SD, mm | 56.0 ± 31.0 |
 Ki-67 index, mean ± SD | 14.6 ± 16.2 |
 Mitosis, 10 HPF, mean ± SD | 4.4 ± 17.0 |
 Chromogranin A positive | 13 |
 Synaptophysin positive | 18 |
 CD-56 positive | 17 |
 Lymph node metastasis | 7 |
 Liver metastasis | 17 |
  Synchronous | 13 |
  Metachronous | 4 |
 Functionality, nonfunctioning | 17 |
Tumor grade | |
 NET-G2 | 15 |
 NET-G3 | 4 |
STZ treatment | |
 Month on treatment, median (range) | 8.0 (0.8–31.7) |
STZ treatment line | |
 2nd | 6 |
 3rd | 6 |
 4th or later | 7 |
